Skip to main content

Gettier Gets Far Too Much Credit

Image result for edmund gettier

There is an old theory of knowledge known as the JTB view: the view, that is, that knowledge is "justified true belief."

Edmund Gettier gets a lot of credit for weakening the hold of JTB upon conventional wisdom, in his brief article of 1963 in the journal ANALYSIS, arguing that there are cases in which all three circumstances are met, but which one wouldn't ordinarily speak of as "knowledge." 

Some people believe Gettier gets more credit than he deserves. Alvin Plantinga has written:

According to the inherited lore of the epistemological tribe, the JTB [justified true belief] account enjoyed the status of epistemological orthodoxy until 1963, when it was shattered by Edmund Gettier... Of course there is an interesting historical irony here: it isn't easy to find many really explicit statements of a JTB analysis of knowledge prior to Gettier. It is almost as if a distinguished critic created a tradition in the very act of destroying it.

Also, Bertrand Russell stated a Gettier type case before Gettier did. It appears in his book HUMAN KNOWLEDGE (1948). Russell writes of a woman named Alice, who looks at a clock where the hands point to 12 and 2. She concludes that it is 2 o'clock. But the clock is no longer working. But (another "but"!) it stopped exactly 12 hours before Alice glanced at it. So it is only a matter of luck that Alice comes to believe that it is the time that it actually is, 2 o'clock.

Does Alice "know" the time or not?

And why does Gettier get the credit? Maybe just because Russell is known for so much else that one might as well grant Gettier this. He is known after all for nothing else! 

Comments

Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.



We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

Hume's Cutlery

David Hume is renowned for two pieces of cutlery, the guillotine and the fork.

Hume's guillotine is the sharp cut he makes between "is" statements and "ought" statements, to make the point that the former never ground the latter.

His "fork" is the division between what later came to be called "analytic" and "synthetic" statements, with the ominous observation that any books containing statements that cannot be assigned to one or the other prong should be burnt.

Actually, I should acknowledge that there is some dispute as to how well or poorly the dichotomy Hume outlines really maps onto the analytic/synthetic dichotomy. Some writers maintain that Hume meant something quite different and has been hijacked. Personally, I've never seen the alleged difference however hard they've worked to point it out to me.

The guillotine makes for a more dramatic graphic than a mere fork, hence the bit of clip art above.

I'm curious whe…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…